Could a nasal spray boost sleep and brain health in seniors?

NCT ID NCT07610343

First seen May 28, 2026 · Last updated Jun 23, 2026 · Updated 6 times

Summary

This study tests whether a nasal spray containing two medicines, dexmedetomidine and esketamine, can improve sleep quality and thinking abilities in older adults with mild-to-moderate Alzheimer's-related cognitive impairment and sleep problems. Sixty participants will receive either the active spray or a placebo twice a week for four weeks. The main goal is to see if sleep quality gets better, with a secondary look at whether thinking skills also improve.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dexmedetomidine and esketamine nasal spray

What this could lead to

If it works, this could point toward a new way to improve sleep and possibly slow cognitive decline in older adults with Alzheimer's disease.

What could go wrong

This is a small, early-phase trial with only 60 participants. The combination may cause side effects like low blood pressure, slow heart rate, or neuropsychiatric issues, and it may not improve sleep or cognition as hoped.

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction sleep disorder sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.